We are live on ! Find out more
ALPN

Alpine Immune Sciences Inc
ALPN

Delisted

ALPN was delisted on the 17th of May, 2024.

Back to rankings

133 hedge funds and large institutions have $1.14B invested in Alpine Immune Sciences Inc in 2023 Q4 according to their latest regulatory filings, with 55 funds opening new positions, 62 increasing their positions, 10 reducing their positions, and 9 closing their positions.

New
Increased
Maintained
Reduced
Closed

520% more repeat investments, than reductions

Existing positions increased: 62 | Existing positions reduced: 10

511% more first-time investments, than exits

New positions opened: 55 | Existing positions closed: 9

460% more call options, than puts

Call options by funds: $140K | Put options by funds: $25K

116% more capital invested

Capital invested by funds: $526M → $1.14B (+$611M)

60% more funds holding in top 10

Funds holding in top 10: 5 → 8 (+3)

51% more funds holding

Funds holding: 88 → 133 (+45)

Holders
133
Holders Change
+45
Holders Change %
+51.14%
% of All Funds
1.94%
Holding in Top 10
8
Holding in Top 10 Change
+3
Holding in Top 10 Change %
+60%
% of All Funds
0.12%
New
55
Increased
62
Reduced
10
Closed
9
Calls
$140K
Puts
$25K
Net Calls
+$115K
Net Calls Change
+$94K

Top Buyers

Rank Fund Capital Flow
1
LCM
Lynx1 Capital Management
Puerto Rico
+$19.6M
2
Morgan Stanley
Morgan Stanley
New York
+$19.2M
3
Franklin Resources
Franklin Resources
California
+$17M
4
Citadel Advisors
Citadel Advisors
Florida
+$11.8M
5
State Street
State Street
Massachusetts
+$10.9M

Top Sellers

Rank Fund Capital Flow
1
O
OrbiMed
New York
-$21.5M
2
AG
Artal Group
Luxembourg
-$15.9M
3
GTC
Ghost Tree Capital
New York
-$7.6M
4
APM
Avidity Partners Management
Texas
-$7.53M
5
TLP
Tri Locum Partners
New York
-$3.6M
Name Holding Trade Value Shares
Change 		Change in
Stake
Walleye Capital
26
Walleye Capital
New York
$6.97M +$2.5M +179,667 +96%
ABG
27
Ally Bridge Group
New York
$6.81M +$4.96M +357,271 New
SCM
28
Silverarc Capital Management
Massachusetts
$5.68M +$4.14M +297,789 New
Charles Schwab
29
Charles Schwab
California
$5.67M +$878K +63,196 +27%
Northern Trust
30
Northern Trust
Illinois
$5.66M +$365K +26,271 +10%
D.E. Shaw & Co
31
D.E. Shaw & Co
New York
$5.63M +$3.43M +246,911 +508%
Millennium Management
32
Millennium Management
New York
$5.2M +$2.64M +190,140 +229%
Two Sigma Advisers
33
Two Sigma Advisers
New York
$5.03M +$250K +18,000 +7%
NFGH
34
Nan Fung Group Holdings
Hong Kong
$5.03M +$1.13M +81,660 +45%
SC
35
Stempoint Capital
New York
$4.69M +$3.42M +246,178 New
Invesco
36
Invesco
Georgia
$4.61M +$342K +24,640 +11%
Fidelity Investments
37
Fidelity Investments
Massachusetts
$4.55M -$3.14M -226,266 -49%
SFM
38
Sphera Funds Management
Israel
$4.48M +$762K +54,841 +30%
Dimensional Fund Advisors
39
Dimensional Fund Advisors
Texas
$4.46M +$925K +66,573 +40%
Voloridge Investment Management
40
Voloridge Investment Management
Florida
$4.46M +$3.25M +233,750 New
Marshall Wace
41
Marshall Wace
United Kingdom
$4.21M +$3.07M +221,118 New
Renaissance Technologies
42
Renaissance Technologies
New York
$4.13M -$993K -71,509 -25%
ECM
43
ExodusPoint Capital Management
New York
$3.98M -$112K -8,081 -4%
Qube Research & Technologies (QRT)
44
Qube Research & Technologies (QRT)
United Kingdom
$3.92M +$2.72M +195,696 +1,943%
Goldman Sachs
45
Goldman Sachs
New York
$3.77M +$1.83M +131,499 +198%
Hudson Bay Capital Management
46
Hudson Bay Capital Management
Connecticut
$3.76M +$2.74M +197,019 New
EAM
47
Exome Asset Management
New York
$3.31M +$2.41M +173,500 New
EI
48
EAM Investors
California
$3.1M +$2.26M +162,685 New
Jennison Associates
49
Jennison Associates
New York
$2.69M +$1.96M +141,095 New
Ensign Peak Advisors
50
Ensign Peak Advisors
Utah
$2.48M +$1.81M +129,975 New
1
2
3 4 5

ALPN Hedge Fund Activity: Q4 2023 in Review

133 of the 6,859 institutional investors tracked by Wall St. Rank reported a position in Alpine Immune Sciences Inc (ALPN) for Q4 2023, worth a combined $1.14B — up 116% from $526M a quarter earlier.

Buyers outnumbered sellers: 55 funds opened new ALPN positions and 9 closed out — a net gain of 46 holders — while 62 added to existing stakes and 10 trimmed.

The largest buyer was Lynx1 Capital Management, adding an estimated $19.6M. The largest seller was OrbiMed, cutting an estimated $21.5M.

  • 133 institutional investors held Alpine Immune Sciences Inc (ALPN) as of Q4 2023, up from 88 in Q3 2023.
  • Funds reported $1.14B of Alpine Immune Sciences Inc stock for Q4 2023, up 116% quarter-over-quarter.
  • 55 funds opened new Alpine Immune Sciences Inc positions in Q4 2023 and 9 closed out, a net change of +46 holders.
  • The largest Alpine Immune Sciences Inc buyer in Q4 2023 was Lynx1 Capital Management, an estimated $19.6M added.
  • The largest Alpine Immune Sciences Inc seller in Q4 2023 was OrbiMed, an estimated $21.5M sold.

Based on aggregated 13F filings for Q4 2023.